At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
AZD5423 +3 moredrug
Likely dose
Budesonide 200 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Double-dummy, Randomised, Placebo-controlled, 4-way, Crossover, Multi-centre Phase II Study With Budesonide as an Active Control to Evaluate the Efficacy and Safety of 2 Doses of Inhaled AZD5423 Over 7 Days in Patients With Mild Allergic Asthma Challenged With an Inhaled Allergen
In Brief
A Phase 2 clinical trial evaluating AZD5423, Budesonide 200 microgram, and 1 other intervention for Asthma. Completed, enrolled 27 participants across 4 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy of AZD5423 in patients with mild asthma challenged with an inhaled allergen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartNov 2010
Primary CompletionDec 2011
TodayJul 2026
First PostedOct 21, 2010
Enrollment StartNov 1, 2010
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.7 years ago
Interventions
AZD5423drug
Suspension for nebulisation once daily 7 days
Budesonide 200 microgramdrug
Dry powder for inhalation twice daily 7 days
Placebodrug
Solution for nebulisation once daily 7 days
Placebodrug
Solution for nebulisation once daily 7 days